JP2023544142A - ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した加齢黄斑疾患を処置する方法 - Google Patents

ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した加齢黄斑疾患を処置する方法 Download PDF

Info

Publication number
JP2023544142A
JP2023544142A JP2023519465A JP2023519465A JP2023544142A JP 2023544142 A JP2023544142 A JP 2023544142A JP 2023519465 A JP2023519465 A JP 2023519465A JP 2023519465 A JP2023519465 A JP 2023519465A JP 2023544142 A JP2023544142 A JP 2023544142A
Authority
JP
Japan
Prior art keywords
promoter
mir
aimp2
seq
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544142A5 (https=
Inventor
ジン ウ チェ，
キュンファ ベク，
Original Assignee
ジェネロス カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネロス カンパニー， リミテッド filed Critical ジェネロス カンパニー， リミテッド
Publication of JP2023544142A publication Critical patent/JP2023544142A/ja
Publication of JP2023544142A5 publication Critical patent/JP2023544142A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023519465A 2020-09-30 2021-09-30 ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した加齢黄斑疾患を処置する方法 Pending JP2023544142A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085922P 2020-09-30 2020-09-30
US63/085,922 2020-09-30
PCT/IB2021/059018 WO2022070142A1 (en) 2020-09-30 2021-09-30 METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF

Publications (2)

Publication Number Publication Date
JP2023544142A true JP2023544142A (ja) 2023-10-20
JP2023544142A5 JP2023544142A5 (https=) 2025-03-06

Family

ID=80949802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519465A Pending JP2023544142A (ja) 2020-09-30 2021-09-30 ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した加齢黄斑疾患を処置する方法

Country Status (8)

Country Link
US (1) US20240050527A1 (https=)
EP (1) EP4221760A4 (https=)
JP (1) JP2023544142A (https=)
KR (1) KR20230110503A (https=)
CN (1) CN116406304A (https=)
AU (1) AU2021354969A1 (https=)
CA (1) CA3192711A1 (https=)
WO (1) WO2022070142A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터
CN119587566A (zh) * 2022-07-22 2025-03-11 郑州大学 一种干预或治疗视网膜色素变性的生物制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521398A (ja) * 2004-11-24 2008-06-26 ソウル ナショナル ユニバーシティー インダストリー ファウンデーション 癌の診断と治療のためのａｉｍｐ２ｄｘ２の用途
JP2008545406A (ja) * 2005-05-27 2008-12-18 フォンダツィオーネ セントロ サン ラファエレ デル モンテ タボール 遺伝子ベクター
KR20170041363A (ko) * 2015-10-07 2017-04-17 원광대학교산학협력단 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
WO2020188472A1 (en) * 2019-03-15 2020-09-24 Generoath Co., Ltd. Vectors containing aimp2-dx2 and target nucleic acids for mir-142 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
US10716866B2 (en) * 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521398A (ja) * 2004-11-24 2008-06-26 ソウル ナショナル ユニバーシティー インダストリー ファウンデーション 癌の診断と治療のためのａｉｍｐ２ｄｘ２の用途
JP2008545406A (ja) * 2005-05-27 2008-12-18 フォンダツィオーネ セントロ サン ラファエレ デル モンテ タボール 遺伝子ベクター
KR20170041363A (ko) * 2015-10-07 2017-04-17 원광대학교산학협력단 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
WO2020188472A1 (en) * 2019-03-15 2020-09-24 Generoath Co., Ltd. Vectors containing aimp2-dx2 and target nucleic acids for mir-142 and uses thereof

Also Published As

Publication number Publication date
CA3192711A1 (en) 2022-04-07
CN116406304A (zh) 2023-07-07
KR20230110503A (ko) 2023-07-24
WO2022070142A1 (en) 2022-04-07
AU2021354969A1 (en) 2023-07-27
EP4221760A1 (en) 2023-08-09
US20240050527A1 (en) 2024-02-15
EP4221760A4 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
JP7503590B2 (ja) 遺伝子構築物
JP2023544142A (ja) ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した加齢黄斑疾患を処置する方法
CN104321069A (zh) 编码视杆细胞来源的视锥细胞活力因子的载体
JP2022513454A (ja) ＡＩＭＰ２－ＤＸ２およびｍｉＲ－１４２の標的核酸を含むベクター、ならびにその使用
JP2023545229A (ja) 抗ｖｅｇｆ実体および負の補体調節因子をコードする核酸、ならびに加齢黄斑変性の処置のためのその使用
JP2003522160A (ja) 眼関連疾患の治療のための遺伝子治療
KR20190046628A (ko) 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
JP2024525183A (ja) 網膜障害
JP2023544141A (ja) ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２の標的配列ならびにその組成物を使用した神経系疾患を処置する方法
WO2025103416A1 (zh) 用于老年相关性黄斑变性的治疗的基因治疗药物
EA048792B1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ВОЗРАСТНОЙ МАКУЛОДИСТРОФИИ С ПРИМЕНЕНИЕМ AIMP2-DX2 И, НЕОБЯЗАТЕЛЬНО, ПОСЛЕДОВАТЕЛЬНОСТИ-МИШЕНИ ДЛЯ miR-142 И ИХ КОМПОЗИЦИЙ
JP2025516639A (ja) ＡＩＭＰ２－ＤＸ２および必要に応じてｍｉＲ－１４２に対する標的配列を使用して網膜変性疾患を処置する方法ならびにその組成物
US20220331241A1 (en) Treatment of x-linked juvenile retinoschisis
KR102626543B1 (ko) AIMP2-DX2 및 miR-142의 표적 핵산을 포함하는 재조합 벡터
CA3001036C (en) Recombinant vectors encoding tyrosine kinase receptor b and agonists thereof
CN120641137A (zh) 重组腺相关病毒载体
Chen et al. AAV2 Delivery of Flt23k Intraceptors Inhibits Murine Choroidal Neovascularization 2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260116